

PRESS RELEASE

02 June 2023 13:30:00 CEST

Senzime Capital Markets Update: Focus on growth and targets remain firm

Uppsala, June 2, 2023. Senzime AB (publ) will give an update on strategy, business and key figures at today's investor event.

Highlights that Senzime will present at today's digital investor event, which starts at 14:00, includes:

- Senzime aims to become a global leader in patient monitoring to help eliminate anesthesia and respiratory complications. There is now a technology shift in the market that supports new innovative products.
- Sales continue to develop very positively, and YTD May 2023 sales have tripled compared to the same period last year. Driving forces are the US market and the support of new clinical guidelines.
- Sales are largely driven by disposable sensors and increased utilization of the TetraGraph system. The number of disposable sensors sold is estimated to be close to 40,000 in the first half of 2023 - an increase from approximately 15,000 sensors sold in the first half of 2022.
- As of the end of May 2023, the company had 139 hospitals as active customers, compared to 111 at the end of 2022.
- The business objective is to reach a utilization rate that exceeds five TetraSens per TetraGraph per week. The previously communicated financial goals for 2025 stand firm with estimated net sales of SEK 275 - 325 million in 2025, as well as a long-term EBITDA margin that is estimated to exceed 40 percent. Senzime's goal is to reach a market share of at least 10 percent in its active market segments.

"Senzime is now in the middle of the growth phase we have strategically and methodically worked towards. We have a strong focus on the US market, a leading and innovative product portfolio supported by new clinical guidelines, and we are well positioned to continue our growth journey and achieve long-term high profitability", says Philip Siberg, CEO, Senzime.

The presentation will be held in Swedish.

Date and time

Friday, June 2, 2023, at 14.00-15.00

Link:

The investor event is broadcast live via this link: https://www.youtube.com/watch?v=eoKlv_h4otc

For further information, please contact:

Philip Siberg, CEO of Senszime AB

Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO

Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senszime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senszime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

[Senzime Capital Markets Update: Focus on growth and targets remain firm](#)